SUMMARY
INTRODUCTION
Prior to cell division, cells must accurately duplicate their genetic material to ensure that both daughter cells contain a full complement of genes. The process of DNA replication is carried out by a large and dynamic macromolecular assembly known as the replisome, which co-ordinates unwinding of the DNA duplex with DNA synthesis of both leading and lagging strands (Pellegrini and Costa, 2016) . Because replicative DNA polymerases cannot initiate the synthesis of new DNA, they rely on a DNA-dependent RNA polymerase known as primase to produce short RNA oligonucleotides that act as primers (Frick and Richardson, 2002) . Primase therefore plays an essential role in DNA replication, priming the synthesis of both the leading and lagging strand.
Human primase is a heterodimeric enzyme comprising two subunits: Pri1 (49.9 kDa, also known as PriS or p49) and Pri2 (58.8 kDa, also known as PriL or p58), encoded by the PRIM1 and PRIM2 genes, respectively (Lucchini et al., 1987) .
PRIM1 maps to a region of chromosome 12 that is amplified in numerous tumour types (Cloutier et al., 1997; Yotov et al., 1999) . In addition, elevated PRIM1 expression has been observed in breast tumour tissues, correlating with poorer patient outcomes (Lee et al., 2018) . It has therefore been suggested that primase may represent an effective target for anti-cancer therapy. More recently, a CRISPR genome-wide dropout screen identified PRIM1 as an essential gene in all 7 cancer cell lines tested (Tzelepis et al., 2016) . Synthetic lethality has been demonstrated between PRIM1 and ATR across a range of cancer cell lines, 5 2017). However, treatment is often associated with thrombocytopenia, anemia, neutropenia and profound lymphopenia, thereby increasing the risk of opportunistic infections (Lukenbill and Kalaycio, 2013; Fidias et al., 1996) . In fact, one of the major problems with the therapeutic use of current nucleoside analogues is dose-limiting toxicity due to their non-selective nature, with potential targets including DNA and RNA polymerases, ribonucleotide reductase and DNA ligase (Parker et al., 1988; Tseng et al., 1982; White et al., 1982; Yang et al., 1992; Huang et al., 1990; Wisitpitthaya et al., 2016; Huang and Plunkett, 1991) .
Vidarabine-TP and Fludarabine-TP are potent inhibitors of DNA replication in vivo (Plunkett et al., 1980) , and have been shown to inhibit both replicative DNA polymerases and primase in vitro (Dicioccio and Srivastava, 1977; Yoshida et al., 1985; Parker and Cheng, 1986) . Primase incorporates ara nucleotides into primers more efficiently than normal ribonucleotides (Catapano et al., 1993; Harrington and Perrino, 1995; Kuchta et al., 1992) , and it has been suggested that primase inhibition may be one of the primary mechanisms for Fludarabine cytotoxicity in tumour cells (Kuchta and Willhelm, 1991; Catapano et al., 1993; Catapano et al., 1991) . However, deciphering which of the many nucleotidebinding enzymes are the primary targets of the ara nucleotides in vivo has proved difficult, with the result that their mechanism of cytotoxicity is still unclear.
A drug that selectively inhibits primase without significant off-target effects could be of significant therapeutic value, and may be less toxic to non-dividing cells (Moore et al., 2002) . Importantly, recent structural information has made the design of high affinity primase inhibitors a more realistic prospect (Kilkenny et al., 6 2013; Vaithiyalingam et al., 2014) . Here we test the effect of a range of chemotherapeutic nucleotide analogues on primase activity. We also present the x-ray crystal structures of human Pri1 bound to Vidarabine-TP and Fludarabine-TP, thereby elucidating the mode of binding of arabinofuranosyl nucleotides to the catalytic subunit of primase, and explaining the reported preference of primase for these nucleotides. We propose that these ara nucleotides represent an interesting starting point for the structure-based drug design of specific primase inhibitors.
RESULTS

Inhibition of RNA primer synthesis by Vidarabine-TP and Fludarabine-TP
To confirm that ara nucleotides are effective inhibitors of human primase, we analysed their effect on RNA primer synthesis. A fluorescence-based RNA primer synthesis assay (Koepsell et al., 2005) revealed strong inhibition of primase activity by both Vidarabine-TP and Fludarabine-TP (Fig. 1B, C) . While similar levels of inhibition were observed for both compounds, no inhibition was observed in the presence of 2F-ATP, confirming that it is the arabinofuranosyl moiety that is important for mediating the inhibitory effect of these nucleotide analogues. Inhibition occurred irrespective of whether the divalent metal was Mn 2+ (Fig. 1B) or Mg 2+ (Fig. 1C) . While both divalent metals support robust primer synthesis in vitro, Mn 2+ has been reported to enhance the binding of nucleotides to human primase, but also to reduce the fidelity of various polymerases including primase (Kirk and Kuchta, 1999; Vaithiyalingam et al., 2014) .
These results were confirmed using denaturing gel electrophoresis to analyse the priming reaction products in the presence of increasing concentrations of Fludarabine-TP ( Fig. 2A) . We observed strong dose-dependent inhibition of RNA primer synthesis, with almost complete inhibition evident even at sub- An RNA primer with Fludarabine incorporated at its 3¢-end could not be further extended with ATP, suggesting that incorporation and capping of the growing ribonucleotide chain is a likely mechanism of action ( Fig. 2C ). This is in agreement with previous primase studies which also describe chain termination by ara nucleotides (Huang et al., 1990; Catapano et al., 1993; Richardson et al., 2004 
X-ray crystal structures of Fludarabine-TP and Vidarabine-TP bound to the Pri1 elongation site
Primase initiates RNA primer synthesis using two distinct nucleotide binding pockets: (i) the initiation site, which utilises several key residues on Pri2-CTD to bind the nucleotide that will be incorporated at the 5¢-end of the primer and (ii) the Pri1 elongation site that binds all subsequent nucleotides (Baranovskiy et al., 2016; . Following synthesis of the first di-nucleotide, which involves both Pri1 and Pri2, further nucleotide addition requires only the elongation site on Pri1 , (Klinge et al., 2007; Zerbe and Kuchta, 2002 Supplementary Fig. 1 ). For each nucleotide soak, the electron density map clearly revealed a single nucleotide bound to the elongation pocket of Pri1 ( Supplementary Fig. 2 A-E). Data collection and refinement statistics are given in Table 1 .
This high-resolution structural information allowed us to compare in detail the interactions of the different sugar moieties within the active site. As described previously, human Pri1 adopts the mixed a/b primase (Prim) fold characteristic of eukaryotic and archaeal primases, with a catalytic triad comprising Asp109, Asp111 and Asp306 which together co-ordinate two divalent metal ions (Kilkenny et al., 2013; Copeland and Tan, 1995) . As seen in previous nucleotide-bound Pri1 crystal structures, the triphosphate moiety of the nucleotide resides in a basic pocket formed by the side-chains of residues Arg162, Arg163, His166, Lys318 and His324, as well as the two Mn 2+ ions co-ordinated by the catalytic aspartates ( Supplementary Fig. 2F ) (Kilkenny et al., 2013; Vaithiyalingam et al., 2014) . By superposing the apo and nucleotide-bound structures, we observe that the loop containing Asp306 needs to move towards the active site to allow the Asp306 side-chain to co-ordinate the second Mn 2+ ion effectively (Supplementary could not be reliably modeled for either chain of the asymmetric unit ( Supplementary Fig. 2D ).
In all structures, the sugar moiety is positioned by the formation of a hydrogen bond between the ribose 3¢-OH and the main-chain amide NH of Lys318 (Fig.   4A ). This interaction is important for catalysis because Cordycepin-TP (3¢-deoxyadenosine triphosphate) is not efficiently polymerised onto an existing RNA primer and only starts to inhibit RNA primer synthesis when present in excess of ATP ( Supplementary Fig. 4 ). In addition to this hydrogen bond, C4 and C5 of the ribose moiety pack on top of the aliphatic side-chain of Leu317. In the ATP-and 2F-ATP-bound structures, the 2¢-OH of the ribose inserts between the main-chain carbonyl group of Leu316 and the carboxyl group of the Asp79 side-chain and is positioned roughly equidistant between these two moieties. However, in the Vidarabine-TP and Fludarabine-TP bound structures, the 2¢-OH points directly towards the carboxyl group of Asp79 and the e-amino group of Lys77, and away from the carbonyl O of Leu316 (Fig. 4A ). In this way, the ara nucleotides present the 2¢-OH in an orientation that is more favourable for hydrogen bond formation compared to the normal ribonucleotides (distances from ara 2¢-OH to Asp79 carboxylate-O range from 2.9 to 3.3 Å and from ara 2¢-OH to Lys77 e-N range from 2.8 to 3.5 Å). The fluorine atom on the base moiety of Fludarabine-TP resides above the side-chain of Leu316 (Fig. 4A) , and only 3.6-3.9 Å away from the side-chain of the catalytically essential residue Arg56 (Kilkenny et al., 2013) .
This pocket could certainly be explored further in future structure-based drug design efforts.
The Vidarabine-TP and Fludarabine-TP crystal structures indicate that the sidechain of residues Lys77 and/or Asp79 may be responsible for the observed preference of primase for ara nucleotides. To test this hypothesis, we generated and purified K77A and D79A point mutants of Pri1. Size exclusion chromatography was used to confirm that these mutants were not mis-folded ( Supplementary Fig. 5 ). We then performed nucleotide binding experiments with the Pri1 point mutants, using the FP competition assay described above. The K77A mutant showed comparable IC50 curve profiles to wild-type Pri1 (Fig. 4B ).
In the case of the D79A mutant, however, the competition curves for the ara nucleotides were indistinguishable from that of dATP, with the IC50 for Fludarabine-TP increasing from 1.13 μM to 2.60 μM, and the IC50 for dATP decreasing from 3.34 μM to 2.09 μM (Fig. 4C) . These results indicate that Asp79 does play a role in distinguishing between different configurations of the sugar moiety. However, the D79A point mutant was still inhibited by Fludarabine-TP and Vidarabine-TP ( Supplementary Fig. 6C ), possibly indicating some redundancy between Asp79 and Lys77 in providing hydrogen bonding to the ara 2'-OH of the ribose.
The ara 2¢-OH is crucial for mediating effective primase inhibition
To investigate whether primase inhibition is a shared property of chemotherapeutic nucleotide analogues, we examined RNA primer synthesis activity in the presence of an extended repertoire of these agents, including
Gemcitabine-TP, Cytarabine-TP and Clofarabine-TP (Fig 1A) . On a ssDNA template, titration of Cytarabine-TP resulted in very similar levels of primase inhibition to Fludarabine-TP (Fig. 5A ). Given that Cytarabine-TP and Fludarabine-TP are CTP and ATP analogues, respectively, this experiment was conducted using a ssDNA template containing equal quantities of T and G. This result was corroborated in a fluorescence-based primer synthesis assay, which showed similar levels of inhibition for Fludarabine-TP, Vidarabine-TP and Cytarabine-TP (Fig. 5B ). In addition, Cytarabine was readily incorporated into an existing RNA primer, as described previously ( Supplementary Fig. 7B ) (Richardson et al., 2004) . These results further confirm that primase inhibition by ara 2¢-OH nucleotide analogues is largely unaffected by the nature of the base moiety.
By contrast, Gemcitabine-TP and Clofarabine-TP, which both contain an ara 2¢-F rather than ara 2¢-OH, did not inhibit RNA primer synthesis over the range of concentrations tested (Fig. 5C ). In addition, in an FP-based competition binding experiment, Gemcitabine-TP and Clofarabine-TP showed very similar IC50 values to ATP ( Supplementary Fig. 7 A) . This is consistent with the structural data presented here, as an ara 2¢-F would be unable to form a favourable hydrogen bond with the carboxylate side-chain of Asp79. Interestingly, in the presence of nucleotide analogue alone, while Clofarabine was poorly incorporated into an existing RNA primer, Gemcitabine was readily incorporated (Supplementary Fig.   7B ). We conclude that, while primase can incorporate Gemcitabine into RNA primers, this analogue does not exert significant inhibition of primer synthesis in the presence of the natural ribonucleotides. This is probably due to its weaker binding affinity compared to the ara 2¢-OH nucleotide analogues. Taken together, these results indicate that a hydrogen bond donor in the 2¢ position of the arabinose sugar moiety is crucial for mediating effective primase inhibition by these nucleotide analogues.
DISCUSSION
We have analysed in detail the mode of binding of anti-cancer agent
Fludarabine-TP and anti-viral agent Vidarabine-TP to human primase. Thermal denaturation, competition and primer synthesis experiments all confirm that these arabinofuranosyl nucleotides are bona fide inhibitors of primase, as is the CTPanalogue, Cytarabine-TP. We find that Asp79 contributes to the preference of primase to bind ara nucleotides over ribo-and deoxyribonucleotides, and attribute this, at least in part, to the formation of a favourable interaction between the ara 2¢-OH and the carboxylate side-chain of Asp79 (Fig. 4A ).
Given that these ara nucleotides inhibit primase to a significant degree in the presence of excess normal ribonucleotides in vitro ( Fig. 2A, Fig. 5A ), and the fact that Fludarabine-TP can accumulate to concentrations in the range of hundreds of micromolar inside cells (Gandhi and Plunkett, 2002) , it is possible that primase may indeed be one of the relevant targets of this chemotherapeutic agent in vivo.
Whether primase inhibition by Fludarabine-TP or Cytarabine-TP is one of the primary modes of cytotoxicity towards cancer cells remains to be determined, and will be the subject of future experiments.
Gemcitabine, Cytarabine, Fludarabine and Clofarabine are all used as cytotoxic anti-cancer agents in the clinic but, despite structural similarities, their mode of action seems to vary quite significantly. A recent structural and biochemical study of the interaction of various chemotherapeutic nucleotide analogues with SamHD1, an enzyme that regulates dNTP levels, has important implications for drug turnover and hence efficacy (Srikanth et al., 2018) . In addition, human
PrimPol has been shown to incorporate Cytarabine-TP and Gemcitabine-TP, but not two antiviral nucleoside analogues (Emtricitabine and Lamivudine), into newly-synthesised DNA strands (Tokarsky et al., 2017) . These recent studies highlight how important it will be to analyse the effect of each nucleotide analogue on a range of intracellular targets in order to begin to understand their nuanced activity in vivo.
The data presented here indicate that chemotherapeutic nucleotides Cytarabine-TP and Fludarabine-TP, but not Gemcitabine-TP or Clofarabine-TP, are likely to be effective inhibitors of primase activity in vivo. They display higher binding affinity to human primase than the natural ribonucleotides (Fig. 3A) , are efficiently incorporated into RNA primers (Fig. 2B, Supplementary Fig. 7B ) and have the potential to induce chain termination of nascent RNA primers (Fig. 2C) . Thus it is likely that their inhibitory action is a result of both competitive inhibition and capping of the RNA primer resulting in chain termination.
It should now be possible to build on previous work outlining the synthesis of novel ara nucleotide analogue compounds as potent primase inhibitors (Moore et al., 2002) . Initial work was promising, describing a nucleotide analogue (araBTP) with improved selectivity for primase over DNA polymerase a, but further advances were hindered by a lack of structural information relating to the mode of binding of this agent to the primase active site. Based on the structural data presented here, we hypothesise that it should be possible to further optimise the binding of ara nucleotides to Pri1, in order to generate a higher affinity, more selective inhibitor of human primase. In the longer term, this may result in a new chemotherapeutic agent that has less severe side-effects than Fludarabine, by minimising cytotoxicity that results from off-target effects. In addition, structural information of this kind will enable the refinement of individual therapeutic nucleotide analogues so that they interact with specific combinations of intracellular targets, thereby modulating their effect in vivo.
MATERIALS AND METHODS
Nucleotides and nucleotide analogues
2F-ATP (NU-145S), Vidarabine-TP (NU-1111S), Fludarabine-TP (NU-10703-10),
Gemcitabine-TP (NU-1607S), Clofarabine-TP (NU-874), Cytarabine-TP (NU-1170S) and N 6 -(6-Aminohexyl)-ATP-6FAM (NU-805-6FM) were purchased from Jena Bioscience.
Cloning, expression and protein purification
Heterodimeric human primase (Pri1-Pri2) was co-expressed in bacteria as fulllength His6-tagged Pri1 (amino acids 1 to 420) and Pri2 (1 to 462). Residues 463 to 509 of Pri2 were omitted to minimise proteolytic degradation. These residues are not conserved and are disordered in the x-ray crystal structure of full-length human primase (Baranovskiy et al., 2016) . Primer synthesis assays confirmed that this protein showed similar activity to the wild-type protein ( Supplementary   Fig. 8 ). Human Pri1 was produced as either full-length His10-tagged Pri1 (1 to 420) for competition experiments, or His10-tagged Pri1 (1 to 407) for crystallisation. K77A and D79A point mutations in full-length Pri1 were generated by site-directed mutagenesis. Due to exposed hydrophobic patches on both Pri1
and Pri2 that interfered with the analysis, thermal melt experiments were performed using a chimeric construct of human primase (Pri1-Pri2 ΔCTD -Pol a chimera), comprising Pol a residues 1445 to 1462 (GYSEVNLSKLFAGCAVKS) fused via a 15 residue Gly-Ser-Thr linker to residue N19 of Pri2. In this protein, the tethered Pol a peptide binds to a hydrophobic patch on the N-terminal domain of Pri2, while the Pri1 elongation site is unaffected (Kilkenny et al., 2013) .
All proteins were expressed in the Rosetta2 (DE3) E. coli strain from the pRSFDuet-1 vector (Novagen). The purification protocol entailed Ni-NTA agarose chromatography (Qiagen), Heparin sepharose chromatography (GE Healthcare), His-tag cleavage by TEV protease, and size exclusion chromatography. The size exclusion buffer comprised either 25 mM HEPES pH 7.2, 300 mM KCl, 5%
glycerol and 1 mM TCEP (for Pri1-Pri2), or 25 mM HEPES pH 7.2, 150 mM KCl, 5% glycerol and 1 mM TCEP (for Pri1). Purified proteins were concentrated and aliquots flash frozen in liquid nitrogen, then stored at -80 °C.
Crystallisation and X-ray crystallography
Apo Pri1 (1 to 407) was crystallised by vapour diffusion at 19 °C, by mixing 1 μl of 150 μM Pri1 with 1 μl of crystallisation buffer (0.1 M Bis Tris propane pH 6.5, 24% PEG 3350, 0.15 M NaF). Diffraction data were collected at SOLEIL synchrotron (beamline PROXIMA 1). The protein crystallized in space group P43212, with one copy of Pri1 in the asymmetric unit. Diffraction data were indexed, integrated and scaled using XDS (Kabsch, 2010) , and the structure solved by molecular replacement in Phaser (McCoy et al., 2007) using 4BPU as the search model (Kilkenny et al., 2013) . The model was completed by alternating between cycles of manual rebuilding in Coot (Emsley et al., 2010 ) and structure refinement in PhenixRefine (Adams et al., 2010) . Unfortunately, while these crystals diffracted to high resolution (1.5 Å), they were often multiple and/or poorly reproducible, and the crystallisation condition was therefore optimised for the nucleotide soaking experiments. (Table 1 ). The apo Pri1 structure described above was used as the molecular replacement model. Data were processed and the model refined as described above. Owing to poor electron density, the following residues were considered disordered and omitted from the final model: apo Pri1 
Gel-based primase activity assays
Each 30 μl reaction contained 20 mM Tris-HCl pH 7.5, 50 mM K(OAc), 1 mM DTT, 0.5 mM NTP, 0.5 μM ssDNA or annealed DNA-RNA template, 0.5 μM Pri1-Pri2, the indicated concentration of nucleotide analogue and either 10 mM Mg(OAc)2 or 1 mM MnCl2. The control reaction contained all components except primase. Reactions were incubated at 37 °C for the indicated time to allow primer synthesis to occur, then terminated by the addition of 30 μl buffer comprising 95% formamide and 25 mM EDTA. Samples were heated to 70 °C for 2 minutes then loaded onto a 18% urea-polyacrylamide gel, which was run at 500 V for 90 minutes in 0.5x TBE buffer. Gels were stained in 0.5x TBE buffer containing a 1:10000 dilution of Sybr Gold Stain (Thermo Fisher Scientific), for 30 min with shaking. Reaction products were visualised by scanning with a 473 nm laser (Typhoon FLA 9000, GE Healthcare).
Fluorescence anisotropy-based nucleotide binding experiments
Binding experiments were performed in triplicate in 96 well plate format. Each well contained 30 nM 6FAM-labelled ATP in 25 mM HEPES pH 7.0, 120 mM NaCl, 1 mM TCEP and 2 mM MnCl2 (or 2 mM MgCl2). Pri1-Pri2 ΔCTD -Pol a chimera was added in increasing concentrations, ranging from 0 to 120 μM ( 
Thermal denaturation
Reactions were performed in quadruplicate, in 96 well plate format. Each well contained 6.3 μM Pri1-Pri2 ΔCTD -Pol a chimera, 500 μM MnCl2, 500 μM nucleotide and 5x SYPRO orange dye (Thermo Fisher Scientific), in a reaction buffer comprising 25 mM HEPES pH 7.0, 150 mM NaCl and 1 mM TCEP. Heating was performed in a CFX Connect Real-time PCR detection system with 96-well reaction module (Bio-Rad), using a ramp rate of 0.2 °C.min -1 . The negative of the first derivative of the fluorescence signal was plotted against temperature, and the melting temperature (Tm) estimated from the local minimum of the curve peak.
Size exclusion chromatography
Protein samples were injected onto a Superdex S200 or S75 16/60 size exclusion column (GE Healthcare), which was run at 1 ml.min -1 in 25 mM HEPES pH 7.0, 200 mM NaCl and 5% glycerol. Eluted fractions were analysed by SDS-PAGE with Coomassie staining.
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